An Open-label Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Subjects With Moderately Impaired Hepatic Function
Latest Information Update: 17 Jan 2020
At a glance
- Drugs Adafosbuvir (Primary) ; Odalasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 10 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Sep 2017 New trial record